Profile picture

Professor Yong Huo

Peking University First Hospital, Beijing (China)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Presentation
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Read more
Stroke prevention from lifestyle to intervention
Presentation
Stroke prevention from lifestyle to intervention
Read more
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Presentation
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Read more

ESC 365 is supported by

novartis Explore sponsored resources